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Prostate cancer is the most common cancer in adult males in the
Western world. Currently in the UK, a significant proportion of
men presenting clinically with prostate cancer have advanced
disease and their treatment remains unsatisfactory. Endocrine
therapy (with either surgical orchiectomy or chemical androgen
ablation) in men with metastatic disease aims for palliation and
gives transient control of the disease for an average of 2 years
(Klein, 1979; Scott et al, 1980). Prostate cancer responds poorly to
combination chemotherapy and novel treatment modalities are
urgently needed. 
For solid tumours such as prostate cancer to develop and
progress, neo-angiogenesis is critical once the tumour volume
reaches 2–3 mm3 (Folkman, 1990). Angiogenesis is tightly con-
trolled by interaction between angiogenic and anti-angiogenic
factors (Bouck et al, 1996). A large number of angiogenic mole-
cules have now been identified including fibroblast growth 
factor-2 (FGF-2 or bFGF) and vascular endothelial growth factor
(VEGF). 
Many peptide growth factors play important roles in the patho-
biology of prostate cancer. They act as mitogens, facilitating
proliferation, invasion and preventing apoptosis. They mediate 
bi-directional interactions between stroma and epithelium as
paracrine agents, further contributing to carcinogenesis and
tumour progression. Peptide growth factors such as insulin-like
growth factors, epidermal growth factors and members of the FGF
families, and their high affinity receptor tyrosine kinases, are
implicated in mediating cellular proliferation in human prostate
cancer (Byrne et al, 1996; Tennant et al, 1996; Dorkin et al,
1999a). 
VEGF is a soluble, dimeric 45 kDa protein that induces vascular
endothelial cell proliferation and vessel hyperpermeability (Senger
et al, 1983; Connolly et al, 1989; Ferrara et al, 1992). Several
tumour cell types secrete it and its high affinity tyrosine kinase
receptors, namely fms-like tyrosine kinase 1 (FLT-1/VEGF
receptor 1) and fetal liver kinase (FLK/KDR/VEGF receptor 2),
are found on vascular endothelial cells (Terman et al, 1992;
deVries et al, 1992; Quinn et al, 1993) and tumour cells (Boocock
et al, 1995; Ferrer et al, 1999). Positive associations have been
demonstrated between tumour VEGF expression and tumour
aggressiveness in several cancers including colon (Takahashi et al,
1995), breast (Toi et al, 1995) and gastric (Maeda et al, 1996)
cancers. 
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Summary Vascular endothelial growth factor (VEGF) mediates neo-angiogenesis during tumour progression and is known to cooperate with
the fibroblast growth factor (FGF) system to facilitate angiogenesis in a synergistic manner. In view of this, we have investigated VEGF
expression in 67 cases of prostate cancer previously characterized for fibroblast growth factor-8 (FGF-8) expression. Cytoplasmic VEGF
staining was detected in malignant cells in 45 out of 67 cases. Cytoplasmic staining was found in adjacent stromal cells in 32 cases, being
particularly strong around nests of invasive tumour. Positive VEGF immunoreactivity in benign glands was restricted to basal epithelium. A
significant association was observed between tumour VEGF and FGF-8 expression (P = 0.004). We identified increased VEGF
immunoreactivity in both malignant epithelium and adjacent stroma and both were found to be significantly associated with high tumour stage
(P = 0.0047 and P = 0.0002, respectively). VEGF expression also correlated with increased serum PSA levels (P = 0.01). Among positively
stained tumours, VEGF expression showed a significant association with Gleason score (P = 0.04). Cases showing positive VEGF
immunoreactivity in the stroma had a significantly reduced survival rate compared to those with negative staining (P = 0.037). Cases with
tumours expressing both FGF-8 in the malignant epithelium and VEGF in the adjacent stroma had a significantly worse survival rate than
those with tumours negative for both, or only expressing one of the two growth factors (P = 0.029). Cox multivariate regression analysis of
survival demonstrated that stromal VEGF and tumour stage were the most significant independent predictors of survival. In conclusion, we
report for the first time a correlation of both tumour and stromal VEGF expression in prostate cancer with clinical parameters as well as its
correlation to FGF-8 expression. © 2001 Cancer Research Campaign http://www.bjcancer.com
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In the prostate, expression of VEGF mRNA and protein has
been reported in the malignant epithelium as well as tumour-
associated stroma and a proportion of non-malignant epithelial
cells (Jackson et al, 1997). Weidner et al (1993) and other groups
have demonstrated a correlation between tumour angiogenesis and
metastatic disease in invasive prostate cancer. In a rat prostate
tumour model, increased VEGF expression was associated with
enhanced microvessel density and metastatic capacity (Haggstrom
et al, 2000). 
Previous in vitro and in vivo work has also suggested that the
VEGF and FGF systems, acting through distinct receptor kinases,
may function in a synergistic manner to enhance angiogenesis and
tumourigenicity (Pepper et al, 1992; Asahara et al, 1995).
Furthermore, FGF-2 may also regulate VEGF expression in
vascular endothelial cells via autocrine and paracrine mechanisms
(Seghezzi et al, 1998). FGF-8, originally identified as the
androgen-induced growth factor (Tanaka et al, 1992), is another
key member of the FGF family involved in tumorigenesis. In
humans, the protein exists as four isoforms, denoted FGF-8a, 8b,
8e and 8f (Gemel et al, 1996). It is widely expressed during
embryogenesis (Heikinheimo et al, 1994), with only low levels of
expression in some normal adult tissues such as testis, prostate and
the brain (Tanaka et al, 1998; Dorkin et al, 1999a). We have previ-
ously characterized the expression of members of the FGF family
in prostate cancer and identified FGF-8 to be most important
(Dorkin et al, 1999b). The b isoform was overexpressed in malig-
nant prostate epithelium; this overexpression correlated with
advanced tumour stage and higher Gleason scores, and persisted in
androgen-independent disease (Dorkin et al, 1999a). Here we
report our study on VEGF immunoreactivity in resected prostate
cancer and describe the correlation between VEGF expression and
clinical parameters, and with the expression of FGF-8. 
MATERIALS AND METHODS 
Patient materials 
A cohort of 67 cases of prostate cancer, diagnosed between 
1989 and 1994 and previously characterized for FGF-1, -2 and 
-8 expression (Dorkin et al, 1999a, 1999b), were included in 
this study. The ages studied ranged from 49–90 years (mean 
68 years) at the time of surgery. The clinical details are outlined 
in Table 1. A total of 23 patients were confirmed to have 
bony metastatic disease on isotopic bone scans, which were
performed in 45 patients in this series. Archival, formalin-fixed,
paraffin-embedded specimens obtained from transurethral resec-
tion of the prostate (TURP) were examined. No men had received
androgen deprivation therapy prior to prostate resection. The
overall median survival rate of the patients studied was 38.5
months. A total of 20 cases of benign prostatic hyperplasia (BPH),
also obtained from TURP, were included in the study. Archival
blocks of endometrium in early proliferative and late secretory
phases of the menstrual cycle were included as positive controls
for VEGF expression (Zhang et al, 1998). 
Immunohistochemistry 
Initial assessment of a mouse monoclonal anti-human VEGF
antibody M293 (R&D Systems, Abingdon, UK) using a variety of
pre-treatment conditions, including microwave, pressure cooker,
trypsin as well as no pre-treatment, failed to provide an optimal
signal. A second anti-VEGF antibody was tested: the goat polyclonal
antibody (AB-293-NA, R&D Systems) provided clean and repro-
ducible signals in our hands without the need for high temperature
antigen retrieval, allowing better tissue morphology. This antibody
has also been preferred for similar reasons in another immunohisto-
chemistry study (Kumar-Singh et al, 1999).
We cut 5 µ m sections from tumour blocks; then they were
mounted onto APES-coated slides, air-dried at 60˚C, de-waxed in
xylene, and then sequentially rehydrated in 100%, 70% and 50%
ethanol. Endogenous peroxidase activity was blocked by incu-
bating sections for 10 min in 9% hydrogen peroxide in distilled
water. Sections were washed in running water for 5 min, and then
incubated in 0.1% trypsin (ICN, Basingstoke, UK) in a 0.1%
calcium chloride solution (BDH, c/o NELS, Co. Durham, UK) at
37˚C (pH 7.6) for 18 min. After a further wash in running water
for 5 min followed by phosphate buffered saline (PBS) for 2 min,
the sections were blocked for 10 min in normal rabbit serum
(GibcoBRL, Paisley, UK) diluted 1:5 in PBS and then washed in
two changes of PBS over 10 min. The primary antibody was a goat
polyclonal anti-human VEGF antibody (R&D systems, Abingdon,
UK), diluted in normal rabbit serum to a 10 mg/ml stock. Sections
were incubated in primary antibody at 4˚C overnight. Pre-immune
serum was applied as an internal negative control. The slides were
then incubated for 30 min in biotinylated rabbit anti-goat antibody
(Manarini Diagnostics, Wokingham, UK) diluted 1:60 in PBS
at room temperature for 40 min, followed by 2 washes in PBS
over 10 min in total. The sections were then incubated in a strepta-
vidin HRP label (Biomen Supersensitive goat kit) diluted 1:60 in
PBS for 30 min at room temperature, followed by 2 washes in
Table 1 Clinical details 
Stage* Total number  Median serum  Range No. with PSA data  
(n = 65) PSA† (n = 35)
T1 16 14.9 (1.2–65) 4 
T2 10 79.5 (21.4–98.7) 8 
T3 20 30.6 (3–5047) 14 
T4 19 97.3 (3.6–600) 9 
Gleason score n = 67
2–6 9 7.8 (1.2–65) 4 
7 24 22.3 (3.6–446) 11 
8–10 34 82.9 (3–5047) 20 
*T-stage data unavailable for two cases; †Serum PSA at diagnosis – data not available for 32 cases. PSA
values in nanogram ml/ (ng/ml) with range in brackets. 578 AF West et al
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PBS for 10 min each. Finally, sections were incubated in DAB
(3′ 3′ -diaminobenzidinetetrahydrochloride), counterstained with
Carazzis haematoxylin, dehydrated, cleared and mounted. They
were then viewed using a light microscope. 
Expression of FGF-8 had previously been characterized at tran-
script level by in situ hybridization (ISH) (Dorkin et al, 1999a).
Our current pilot data on FGF-8 immunostaining is consistent with
the data from ISH. For the current study, contiguous sections from
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Figure 1 Immunostaining for VEGF expression. (A) Gleason 8, T3M1 prostate cancer with moderate VEGF immunostaining of both tumour epithelium (black
arrows) and adjacent stroma (white arrows). (B) Gleason 7, T4 prostate cancer with negative VEGF expression in tumour epithelium and positive expression in
the peritumoural stroma. (C) VEGF expression in the basal cells of benign glandular epithelium. (D) Section of prostate cancer stained for the neuroendocrine
marker, protein gene product (PGP), showing positivity for NE-type cells. (E) Negative control (no primary antibody) for Figure 1 (A) (all at magnification × 200)VEGF and FGF-8 expression in human prostate cancer 579
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the same tissue blocks were used for each case examined for
VEGF protein expression. 
Scoring of sections 
Two independent observers (AFW and MO’D, a consultant
histopathologist) scored all sections, with no prior knowledge of
clinical data on any of the cases. An agreed scoring system for
intensity of VEGF immunostaining was established by initial
examination and grading of the first 20 cases. The cell type
expressing VEGF was noted and the intensity of VEGF immunos-
taining was scored semiquantitatively as negative (–), weak (+),
moderate (++) or strong (+++). A section was taken as positive
when over 25% of the tumour area stained positively. Stromal
VEGF expression was similarly scored, with sections taken as
positive when at least 25% of the stromal area stained positively.
To analyze the relationships between VEGF expression and the
various clinico-pathologic features, Fisher’s exact probability test
was used. Trends were analyzed using the chi-square test. For
comparison of serum PSA values between groups separated on the
basis of intensity of staining for VEGF, the Mann–Whitney U-test
was used. To analyze the relationship between VEGF expression
and survival, the Kaplan–Meier method was used with differences
in survival between groups examined using the log rank test.
Multivariate Cox regression analysis was used to assess the inde-
pendent predictive value of VEGF in relation to other clinico-
pathologic parameters. P-values of less than 0.05 were considered
statistically significant. 
RESULTS 
Immunohistochemical expression of VEGF in prostate
cancer and BPH 
Positive VEGF staining was observed in malignant prostatic
epithelium in 45 out of 67 sections (67%) (Figure 1A). The
staining pattern was focal and cytoplasmic, with areas of strong or
moderate staining glands showing heterogeneous immunoreac-
tivity and interspersed with areas of weak or negative staining
glands. Just over half (24/45; 53%) of these cases showed pre-
dominantly moderate or strong positive staining. 
VEGF immunostaining was also present in the stroma in 32
(47.8%) of the 67 cases, and was noted to be particularly strong
adjacent to nests of invasive tumour, being weak or negative else-
where. Stromal staining was observed predominantly in fibroblasts
and such peri-tumoural localization appeared not to be related to
the intensity of tumour epithelial immunoreactivity for VEGF
(Figure 1A and B). Vessels were observed in all sections but the
pattern of distribution was not specifically looked at. Vascular
endothelial cells provided an internal positive control for compar-
ison. There was a significant association between VEGF and FGF-
8 expression within tumour cells (P = 0.004), although FGF-8
expression in tumour epithelium did not correlate with VEGF
expression in the adjacent stroma (Table 2). 
In BPH (n = 20), there was prominent staining of the basal cells
of benign glands with weak or negative staining of the luminal
cells and stroma (Figure 1C). Similarly, in cancer sections, adja-
cent benign glands showed VEGF immunoreactivity in the basal
epithelium. 
Increased VEGF in both malignant epithelium and adjacent
stroma was significantly associated with high tumour stage (P =
0.0047 and P = 0.0002, respectively; Table 3). A significant corre-
lation was also observed between high levels of VEGF immuno-
reactivity and increasing serum prostate-specific antigen (PSA)
levels (P = 0.01) (Table 4). There was a weak association between
VEGF expression and Gleason score among the cases positive for
VEGF in tumour cells (Table 5; P = 0.04). 
In this series, 5 men had tumours with neuroendocrine-like (NE-
like) appearances and stained positively for protein gene product
Table 2 Association between tumour FGF-8 expression and VEGF
immunoreactivity in tumour and stroma 
Tumour VEGF Stromal VEGF 
–/+ ++/+++ – /+ ++/+++ 
FGF-8 –/+ 21 4 12 9 
FGF-8 ++/+++ 19 21 18 18 
P = 0.004 P = 0.78 
–/+: negative/weak; ++/+++: moderate/strong. FGF-8 expression data
unavailable in 2 cases; stromal VEGF expression data unavailable in 
10 cases. 
Table 3 Association of VEGF expression with tumour stage 
Tumour VEGF Stromal VEGF 
–/+ ++/+++ – /+ ++/+++
Clinical stage 
T1/2 22 (84.6%) 4 (15.4%) 18 (85.7%) 3 (14.3%) 
T3/4 20 (50%) 20 (50%) 12 (33.3%) 24 (66.6%) 
P = 0.0047 P = 0.0002 
Total n = 66* n = 57†
*T-stage data unavailable in one case; †Stromal VEGF expression data
unavailable for 10 cases. Intensity of VEGF signal –/+: negative or weak;
++/+++: moderate or strong. 
Table 4 Association of VEGF expression with serum PSA 
Tumour VEGF 
–/+ ++/+++ 
Median serum PSA* 26.2 82.5 
Range 1.2–600 7.5–5047 
n = 21 n = 14 
P = 0.01; Mann–Whitney U-test; –/+: negative or weak; ++/+++:
moderate/strong. Serum PSA in ng/ml. 
Table 5 Association of tumour epithelial VEGF
expression and Gleason score 
Tumour VEGF 
– + ++/+++ 
Gleason score 
(n = 67) 
6 and less 5 3 1 
78 8 8  
8–10 7 12 15 
Intensity of VEGF signal –: negative; +: weak; ++/+++:
moderate/strong. P = 0.04 (chi-square test for trend). 580 AF West et al
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(PGP) and chromogranin A, both markers for neuroendocrine cell
type (Figure 1D). All five men had high-grade and high-stage
disease and died from prostate cancer during follow up. The VEGF
immunoreactivity in this subgroup was cytoplasmic and heteroge-
neous, at moderate or strong intensity. 
The level of tumoural and stromal VEGF expression did not
show significant associations with the presence of hot spots on
isotopic bone scans. Of the total number of patients who had died
from prostate cancer at the time of the study (n = 22; 32.8%), with
a median follow up of 27 months (range 6–109 months), 15
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Figure 2 Kaplan–Meier survival curves of 57 patients with prostatic carcinoma grouped according to the presence or absence of VEGF expression in the
peritumoural stroma. A significant difference in disease-specific survival was found between the VEGF + group (n = 32) and the VEGF – (n = 25) group 
(P = 0.037, log rank test) 
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Figure 3 Kaplan–Meier survival curves of 54 patients with prostatic carcinoma grouped according to VEGF expression in peritumoural stroma and FGF-8
expression in tumour epithelium. Group 1 (n = 32): Either FGF8 +/VEGF– or FGF8–/VEGF+ or FGF8–/VEGF–; Group 2 (n = 22): FGF8+/VEGF+. A significant
difference in disease-specific survival was found between the two groups (P = 0.029, log rank test) VEGF and FGF-8 expression in human prostate cancer 581
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(62.5%) showed moderate or strong immunoreactivity for VEGF
within the peri-tumoural stroma. There was no significant age
difference between cases negative for VEGF staining and those
that showed positive staining (P = 0.22). Cases showing such posi-
tive immunoreactivity for VEGF in the peri-tumoural stroma
appeared to have significantly reduced disease-specific survival
rates compared to those cases with tumours that were negative for
stromal VEGF immunoreactivity (P = 0.037; Figure 2). Tumours
expressing both FGF-8 in the malignant epithelium and VEGF in
the adjacent stroma had a significantly worse survival rates than
those cases with tumours negative for both or only expressing one
of the two growth factors (Figure 3; P = 0.029). Although a similar
relationship was also observed between tumour epithelial VEGF
expression, FGF-8 expression and disease-specific survival, the
association was not significant (P= 0.44, data not shown). In a multi-
variate Cox regression analysis, tumour stage (P = 0.04) and stromal
VEGF expression (P = 0.049) were found to be the most significant
independent indicators of disease-specific survival time (Table 6).
DISCUSSION 
In this study, VEGF immunoreactivity in resected malignant
prostatic epithelium occurred in the majority of specimens (45/67,
67%), in keeping with published reports (Ferrer et al, 1997;
Jackson et al, 1997). Of the tumours, 5 had NE-like appearances,
and all stained strongly positive for VEGF, in keeping with data
from other laboratories (Harper et al, 1996; Borre et al, 2000). 
We have semi-quantitatively scored VEGF immunoreactivity in
the per-tumoural stromal cells. This was previously observed in a
qualitative manner (Jackson et al, 1997), but to our knowledge this
report is the first to describe an association of peri-tumoural
stromal VEGF expression in prostate cancer with clinico-
pathologic parameters. Peri-tumoural stromal VEGF immunoreac-
tivity may result from local secretion by the malignant epithelium
and uptake by the stromal cells, or more likely, induction of
stromal VEGF production by tumour-derived factors in a paracrine
fashion, thus propagating the process of neoangiogenesis. The
latter theory is supported by our observation that the levels of
VEGF immunoreactivity in the malignant glands and the adjacent
peri-tumoural stroma were not directly related, consistent with
findings from a recent report (Mazzucchelli et al, 2000). Although
VEGF expression in tumour cells did not correlate significantly
with the expression in adjacent stroma, such a correlation has been
described in other cancers, such as breast cancer (Lee et al, 1998),
and is thought to reflect a common stimulus to VEGF induction. 
We did not specifically attempt to quantitate the extent of
neovascularization, although vessels were noted in all tumour
sections. Microvessel density (MVD) has been shown to be
increased in malignant prostate tissue (Siegal et al, 1995), to corre-
late with pathologic stage (Brawer et al, 1994) and to predict the
development of metastatic disease (Weidner et al, 1993). We have
shown a strong association between stromal VEGF immunoreac-
tivity and tumour stage (P = 0.0002), supporting its potential role
in the enhancement of angiogenesis. Recent studies have demon-
strated a significant association between VEGF expression and
MVD in prostate cancer (Borre et al, 2000; Strohmeyer et al,
2000). We did not identify a positive correlation between VEGF
expression and bone scan-detected metastases. This may be
explained by the presence of micro-metastases not detectable by
conventional bone scans. Alternatively, tumours expressing VEGF
and FGF-8, which are associated with less favourable disease
survival, may behave more aggressively to result in subsequent
metastatic disease. 
The significant association of increased tumour epithelial
VEGF immunoreactivity with higher serum PSA values is also
interesting. Serum PSA is a good marker for tumour bulk in the
clinical management of prostate cancer. In this respect, VEGF
overexpression may indeed enhance neo-angiogenesis to increase
tumour bulk with associated elevated serum PSA. 
VEGF expression in benign glandular epithelium was noted
both within BPH sections and within prostate cancer specimens, as
demonstrated in a previous study (Jackson et al, 1997). In this
study, we further localized VEGF expression in benign glandular
epithelium to the basal cell compartment, where actively dividing
cells renew and differentiate into the luminal prostate epithelium.
Interestingly, expression of the VEGF receptor FLK-1 in BPH
tissue was demonstrated to be localized specifically to this basal
population of cells in a recent study (Ferrer et al, 1999). This,
combined with our findings supports a potential role for VEGF as
an autocrine regulator of basal cell proliferation in BPH. It is also
interesting to note that FGF-8 expression in BPH is also localized
to the basal epithelium (Dorkin et al, 1999a). 
We found that the frequency of high VEGF expression was
significantly greater in cases with higher Gleason scores than with
lower scores. The correlation between increased VEGF expression
in tumour epithelium and higher tumour grades in prostate cancer
has been demonstrated by some investigators (Harper et al, 1996;
Borre et al, 2000), but not by others (Jackson et al, 1997). 
There are in vitro (Pepper et al, 1992) and in vivo (Asahara et al,
1995) data to suggest functional cooperation between VEGF and
FGF-2 in the induction and maintenance of angiogenesis. Recent
data suggests that FGF-8 enhanced in vitro and in vivo growth of
human prostate cancer LNCaP cells, resulting in increased prolifer-
ation rate, invasion capability and tumour bulk (Song et al, 2000).
When co-cultured, FGF-8 transfected LNCaP cells also potently
induced proliferation of prostate stromal cells. Hence FGF-8,
similar to FGF-2, may well be capable of regulating the functions
of the stromal compartment including tumour angiogenesis. 
Using a cohort of patients with prostate cancer that we had
previously characterized for FGF-8 expression, we examined them
for a potential correlation between VEGF immunoreactivity and
FGF-8 expression. Tumour, but not stromal, VEGF expression was
significantly associated with FGF-8 expression. This may reflect a
related mode of induction for their expression, as both FGF-8 and
VEGF expression have been reported to be upregulated by andro-
gens (Tanaka et al, 1992; Joseph et al, 1997). Although other
members of the FGF family are also expressed in the prostate,
neither FGF-1/acidic FGF nor FGF-2/basic FGF were found to
correlate to clinical parameters as closely as FGF-8 did (Dorkin et
al, 1999b). Hence, we postulate that co-expression of VEGF
(particularly stromal) and FGF-8 may have a synergistic effect in
the progression of human prostate cancer. Indeed, such an effect is
Table 6 Cox multivariate regression analysis 
Variable Wald chi-square P-value 
Gleason score (2–7 vs 8–10) 0.313 0.576 
Tumour stage (T1/2 vs T3/4) 4.1 0.04 
Tumour VEGF (–/+ vs ++/+++) 0.702 0.402 
Stromal VEGF (– vs +) 3.85 0.049 582 AF West et al
British Journal of Cancer (2001) 85(4), 576–583 © 2001 Cancer Research Campaign
consistent with our findings on disease-specific survival,
suggesting that tumours expressing both FGF-8 and VEGF had a
less favourable prognosis when compared to tumours either nega-
tive or expressing only 1 of the 2 factors. Multivariate analysis also
reinforces the fact that stromal VEGF expression appears to be of
greater significance than tumour epithelial VEGF expression in
prediction of survival. 
In conclusion, increased VEGF immunoreactivity in prostate
cancer is associated with high-stage disease, higher serum PSA
values, FGF-8 overexpression and worse survival. Expression of
VEGF in the peri-tumoural stroma appears to be particularly
important, especially in relation to prognosis. These findings are
consistent with the role for VEGF as a potent angiogenic agent in
the development and progression of prostate cancer. VEGF expres-
sion, in this study, was examined on TURP specimens. Given the
heterogeneous and multifocal nature of prostate cancer, it would
be useful to examine VEGF and FGF-8 expression in radical
prostatectomy specimens. Examination of the correlation between
overall stromal density in tumour sections and VEGF expression
patterns would also be more accurate using radical prostatectomy
specimens. Information on the immunoreactivity of VEGF and
other peptide growth factors may allow better prediction of
progression and more appropriate treatment protocols may thus be
determined for individual groups of patients. 
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